Report #2864481

Received Oct 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: Sep 19, 2025
Onset: Sep 20, 2025
Days to onset: 1
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	LA

Symptoms (1)

Headache

Symptom narrative

Headache; This non-serious case was reported by a physician via sales rep and described the occurrence of headache in a male patient who received Herpes zoster (Shingrix) for prophylaxis. On 19-SEP-2025, the patient received the 1st dose of Shingrix (left arm). On 20-SEP-2025, 1 days after receiving Shingrix, the patient experienced headache (Verbatim: Headache). On 22-SEP-2025, the outcome of the headache was resolved (duration 2 days). The reporter considered the headache to be related to Shingrix. The company considered the headache to be related to Shingrix. Additional Information: GSK Receipt Date: 22-SEP-2025 Reporter consent to contact was not provided. The batch number was not provided, and we are unable to contact the reporter.